Metastatic Breast Cancer

I typically don’t use cancer labels, such as “survivor” or “thriver,” but when I heard about COVID-19 “long-haulers,” the term resonated with me.

Watch Emily Huskey, Dr. Wendy Baer, Fabienne Ehivet and Lisa Weems answer questions about areas outside of treatment during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Fabienne Ehivet, from Emory Saint Joseph’s Hospital, discuss genetic testing, during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Wendy Baer, from Winship Cancer Institute at Emory University, discuss psychosocial issues, during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Emily Huskey, from the Winship Cancer Institute of Emory University, discuss diet and exercise, during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Kimberly Curseen, Dr. Anna Bausum, Dr. Kevin Kalinsky and Alyncia Mason answer questions about additional care, during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Kevin Kalinsky, from Winship Cancer Institute of Emory University, discuss joining clinical trials, during the CURE Educated Patient Metastatic Breast Cancer Summit.

After seven years, my prosthetic breast, “Rightie,” sprung a leak and needed to be replaced.

Watch Dr. Anna Bausum, Winship Cancer Institute at Emroy University, discuss alternative medicine, during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Kimberly Curseen, from Winship Cancer Institute of Emory University, discuss supportive care, during the CURE Educated Patient Metastatic Breast Cancer Summit.

Receiving a diagnosis of metastatic breast cancer that has spread to the brain can be a frightening time for patients, however a new resource may help guide them through the stressful journey.

Watch Dr. Suchita Pakkala, Dr. Jane Meisel, Dr. Keerthi Gogineni and Kelly Shanahan discuss updates in disease management during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Keerthi Gogineni, from Emory University School of Medicine, discuss the management of triple-negative disease, during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Suchita Pakkala, from Emory University School of Medicine, discuss estrogen receptor-positive disease, during the CURE Educated Patient Metastatic Breast Cancer Summit.

In CURE®’s “Speaking Out” video series, on behalf of Living Beyond Breast Cancer, Dr. Nancy Lin discusses treatment planning for brain metastases in breast cancer and how patients can take part in driving their care.

I hope every patient and their family can feel the caring that two angels standing by a shoulder can bring.

After surviving cancer, I knew what medical upselling looked like, and experienced it firsthand when a clinician tried to send me for more tests than I felt necessary.

Cancer and its treatments can affect oral health, though when I was diagnosed with breast cancer, the thought of seeing the dentist slipped my mind.

Getting other medical opinions for my cancer diagnosis not only saved my life but also taught me self-care.

The findings of the study show that Enhertu should be a new standard of care for patients with HER2-low metastatic breast cancer, according to an expert at Memorial Sloan Kettering Cancer Center.

At a follow-up of more than two years, treatment with a novel drug produced meaningful results in a group of patients with HER3-expressing metastatic breast cancer or metastatic triple-negative breast cancer.

Treatment with Trodelvy resulted in slight survival improvements, when compared with standard of care chemotherapy regimens, in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

I’m not going to worry that I’m changing my own health by saying out loud that this cancer stuff is hard and scary and kills way too many people every single day.

When I was diagnosed with metastatic breast cancer, my oncology nurse ended up becoming a trusted friend.

A small percentage of patients with metastatic breast cancer participating in clinical trials in the U.S. are Black, which, according to a patient living with the disease is a huge concern since it doesn’t represent the general population.

When I was diagnosed with stage 4 cancer, I was comforted by a simple phrase my oncologist told my husband.

Updated trial results showed that the use of Kisqali plus fulvestrant was associated with an approximate 33% decrease in risk of death for women with HR-positive, HER2-negative advanced breast cancer.

After Enhertu showed promising clinical trial results, the Food and Drug Administration agreed to speed up the development and review of the drug for certain patients with unresectable or metastatic breast cancer.

When I was first diagnosed with metastatic breast cancer, I did not know there were so many other people like me until I attended Living Beyond Breast Cancer’s Conference on Metastatic Breast Cancer.

The Food and Drug Administration granted a fast-track designation to Bria-IMT for the treatment of patients with metastatic breast cancer.